Investors often gauge a stock's potential by its daily performance, yet the true measure of value extends far beyond these short-term fluctuations. Tenet Healthcare Corp (THC, Financial), with a notable daily gain of 9.63% and a three-month loss of 10.53%, presents an intriguing case for valuation. With an Earnings Per Share (EPS) of 4.33, one might wonder, is the stock modestly undervalued? This article delves into Tenet Healthcare's valuation, encouraging readers to explore the comprehensive analysis that follows.
Company Introduction
Tenet Healthcare Corp (THC, Financial) stands as a prominent Dallas-based healthcare services organization, operating approximately 60 hospitals and over 550 ambulatory surgery centers and outpatient facilities across the U.S. The company also offers revenue cycle management solutions through its Conifer segment. With a current stock price of $63.74 and a GF Value of $71.76, Tenet Healthcare appears modestly undervalued, suggesting potential for a higher long-term return relative to its business growth. As we delve into the company's financials, we'll uncover the nuances of its market valuation.
Summarize GF Value
The GF Value is a proprietary metric that reflects the intrinsic worth of a stock, integrating historical trading multiples, a GuruFocus adjustment factor, and future business performance forecasts. The GF Value Line serves as a benchmark for the stock's fair trading value. When a stock trades significantly above this line, it's considered overvalued, and conversely, if it's below, there's potential for higher returns. At a market cap of $6.50 billion, Tenet Healthcare's current price suggests it is modestly undervalued, offering an attractive entry point for value investors.
Link: These companies may deliver higher future returns at reduced risk.
Financial Strength
Before investing, it's crucial to assess a company's financial strength. Tenet Healthcare's cash-to-debt ratio of 0.07 places it below 86.91% of its industry peers, indicating a higher risk of permanent loss. With an overall financial strength rating of 3 out of 10, Tenet Healthcare's fiscal health is a concern that investors should not overlook.
Profitability and Growth
Tenet Healthcare's profitability paints a mixed picture. While the company has been profitable in 5 out of the past 10 years, it boasts an operating margin of 11.6%, which is commendable within its industry. However, its revenue growth has been lagging, with a 3-year average annual decline of 1%. Yet, its EBITDA growth rate of 10.1% suggests a potential for value creation, placing it in a better position than half of its industry counterparts.
ROIC vs. WACC
Comparing Tenet Healthcare's Return on Invested Capital (ROIC) to its Weighted Average Cost of Capital (WACC) offers insights into its value creation. With an ROIC of 7.52 and a slightly lower WACC of 7.24, the company is generating cash flow in excess of its capital costs, indicating a positive investment outcome for shareholders.
Conclusion
In summary, Tenet Healthcare (THC, Financial) presents as modestly undervalued. Despite its poor financial condition, the company maintains fair profitability and exhibits a growth profile that surpasses many in the Healthcare Providers & Services industry. To gain a deeper understanding of Tenet Healthcare stock, explore its 30-Year Financials here.
To discover high-quality companies that may deliver above-average returns, visit the GuruFocus High Quality Low Capex Screener.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
